Minetta C Liu
Overview
Explore the profile of Minetta C Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
5752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohara S, Suda K, Sudhaman S, Hamada A, Chiba M, Shimoji M, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100762.
PMID: 39990137
Introduction: Molecular residual disease detected by circulating tumor DNA (ctDNA) has been reported to be predictive of patients' outcomes in various types of cancers after curative intent treatment. Nevertheless, additional...
2.
Radigan R, Kao C, Krainock M, Liu M, Gupta V, Alexander L, et al.
Sci Rep
. 2025 Feb;
15(1):6126.
PMID: 39971963
Distant metastases account for ~ 90% of cancer deaths and major responses with systemic therapy alone for metastatic cancers are so rare that the National Cancer Institute launched the Exceptional...
3.
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al.
J Clin Oncol
. 2025 Feb;
:JCO2400648.
PMID: 39903903
Purpose: Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here,...
4.
Spring L, Scarpetti L, Medford A, Niemierko A, Comander A, Mulvey T, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):2.
PMID: 39774684
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib...
5.
Yu J, He A, Ouf M, Mehta R, Anaya D, Denbo J, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400443.
PMID: 39772829
Purpose: This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively...
6.
Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400667.
PMID: 39693589
Purpose: Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes....
7.
Lander E, Aushev V, Huffman B, Hanna D, Dutta P, Ferguson J, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400288.
PMID: 39642325
Purpose: After neoadjuvant therapy (NAT) and surgery, up to one third and one half of patients with esophagogastric adenocarcinoma with a pathologic complete response (pCR; tumor regression grade 0 [TRG-0])...
8.
Molinari C, Marisi G, Laliotis G, Spickard E, Rapposelli I, Petracci E, et al.
Sci Rep
. 2024 Nov;
14(1):29536.
PMID: 39604448
Post-neoadjuvant therapy (post-NAT) and post-surgical circulating tumor DNA (ctDNA) risk stratification may enhance the management of patients with locally advanced rectal cancer (LARC). In this study, we assessed the prognostic...
9.
Yoo C, Jeong H, Jeong J, Kim K, Lee S, Ryoo B, et al.
J Hepatol
. 2024 Nov;
PMID: 39532185
Background & Aims: Surgery is the only curative therapeutic option for resectable extrahepatic cholangiocarcinoma, but recurrence is common, and prognosis is poor. There is an unmet clinical need for improved...
10.
Campbell M, Wolf D, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher I, et al.
Cell Rep Med
. 2024 Nov;
5(11):101799.
PMID: 39510069
Only a subset of patients with breast cancer responds to immune checkpoint blockade (ICB). To better understand the underlying mechanisms, we analyze pretreatment biopsies from patients in the I-SPY 2...